MDGL

Peers: VKTX IVA ALT NVO SGMT RYTM ARWR LLY GSK NAMS

| Held by: VTI VB XBI VBK VXF FBT IBB SCHA IWP IWR

Index	-
Market Cap	10.14B
Enterprise Value	9.65B
Income	-325.10M
Sales	1.28B
Book/sh	22.68
Cash/sh	36.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	915
IPO	Feb 06, 2007

P/E	-
Forward P/E	77.28
PEG	-
P/S	7.90
P/B	19.36
P/C	12.09
P/FCF	-
EV/EBITDA	-
EV/Sales	7.52
Quick Ratio	2.94
Current Ratio	3.20
Debt/Eq	0.66
LT Debt/Eq	0.66
Option/Short	Yes / Yes

EPS (ttm)	-12.88
EPS next Y	5.68
EPS next Q	-0.86
EPS this Y	53.13%
EPS next Y	194.31%
EPS next 5Y	-
EPS past 3/5Y	9.32% 0.37%
Sales past 3/5Y	- -
EPS Y/Y TTM	-0.28%
Sales Y/Y TTM	149.04%
EPS Q/Q	-4.41%
Sales Q/Q	71.17%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	25.65% 3.46%

Insider Own	6.77%
Insider Trans	-1.41%
Inst Own	103.11%
Inst Trans	-2.74%
ROA	-28.77%
ROE	-53.31%
ROIC	-37.35%
Gross Margin	91.36%
Oper. Margin	-25.13%
Profit Margin	-25.32%
SMA20	-6.15%
SMA50	-12.97%
SMA200	-12.38%
Trades

Shs Outstand	23.09M
Shs Float	21.54M
Short Float	10.19%
Short Ratio	7.36
Short Interest	2.19M
52W High	615.00 -28.62%
52W Low	393.61 11.53%
Volatility	4.00% 3.63%
ATR (14)	16.24
RSI (14)	31.40
Beta	-1.02
Rel Volume	0.00
Avg Volume	298.09K
Volume	23

Perf Week	-6.10%
Perf Month	-15.09%
Perf Quarter	-19.73%
Perf Half Y	-15.04%
Perf YTD	-24.61%
Perf Year	0.74%
Perf 3Y	264.62%
Perf 5Y	491.41%
Perf 10Y	2483.87%
Recom	1.18
Target Price	684.95
Prev Close	437.74
Price	439.00
Change %	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Buy	$704
Sep-23-26	Initiated	Citigroup	Buy	$725
Aug-04-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$605
Jul-27-26	Initiated	Wells Fargo	Overweight	$685
Jan-28-26	Initiated	Barclays	Overweight	$964
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-05-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-03-25	Upgrade	BofA Securities	Underperform → Neutral	$445
Oct-15-25	Initiated	Truist	Buy	$580
Sep-04-25	Resumed	H.C. Wainwright	Buy	$500
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy	$236 → $422
Feb-27-25	Reiterated	H.C. Wainwright	Buy	$400 → $405
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform

Show Previous Ratings

Oct-26-26 05:16PM	Madrigal Needs ResDifera Volume To Outrun Pricing And Cost Pressure As Shares Hit Lows (Earnings Whispers)
Oct-20-26 08:00AM	Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 (GlobeNewswire)
Oct-15-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-06-26 08:00AM	Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants (GlobeNewswire)
Sep-16-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Sep-02-26 08:00AM	Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-20-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-26 10:01PM	John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact (GuruFocus.com)
Aug-12-26 08:00AM	Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors (GlobeNewswire)
Aug-06-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-04-26 09:37AM	Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly) +5.30%
Jul-30-26 07:11AM	Madrigal: Q2 Earnings Snapshot (Associated Press) -9.83%
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-27-26 10:38AM	CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners (Stocktwits)
04:05PM	Loading…
Jul-21-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-16-26 08:00AM	Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 (GlobeNewswire)
Jul-13-26 07:47PM	MDGL Stock In Focus Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug (Stocktwits)
08:00AM	Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio (GlobeNewswire)
Jul-06-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-29-26 05:00AM	3 late-stage MASH drugs that could rival Rezdiffra (Pharma Voice)
Jun-22-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 08:00AM	Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 (GlobeNewswire) +7.79%
May-27-26 08:00AM	Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH (GlobeNewswire)
May-21-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-26 08:00AM	Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk (GlobeNewswire)
May-07-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 10:46AM	Madrigals (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion (InvestorsHub) +7.42%
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press)
07:00AM	Loading…
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:30AM	Avalo shares spike on skin drug data; BioNTech to cut staff (BioPharma Dive)
06:29AM	Arrowhead and Madrigal sign global licence for MASH RNAi therapy (Pharmaceutical Technology)
May-05-26 11:53AM	Madrigal outlays $1bn for Arrowheads siRNA MASH asset (Pharmaceutical Technology)
08:00AM	Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline (GlobeNewswire)
08:00AM	Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals (Business Wire)
Apr-22-26 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 (GlobeNewswire)
Apr-21-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-07-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-26 08:49PM	The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step (PR Newswire)
Mar-24-26 10:00AM	Advanced Cell-based Therapy Booming the Success for Healthcare Sector (PR Newswire)
Mar-19-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-26 08:01AM	What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy (Insider Monkey)
Mar-05-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-03-26 02:21AM	Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success (Insider Monkey)
Feb-24-26 08:00AM	Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-20-26 09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
05:23AM	Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi (BioPharma Dive)
Feb-19-26 02:03PM	Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... (GuruFocus.com) -11.11%
10:27AM	Madrigal Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:15AM	Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:20AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-17-26 06:08PM	John Paulson's Strategic Moves: Madrigal Pharmaceuticals Inc. Sees a -3.09% Impact (GuruFocus.com)
04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 02:11PM	What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
Feb-12-26 11:43AM	Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal (Pharmaceutical Technology)
10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:00AM	Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-11-26 11:40AM	MKKGY or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
06:25AM	Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH (PR Newswire)
06:00AM	Madrigal turns to RNAi drugs from China to bolster MASH pipeline (BioPharma Dive)
05:00AM	Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs (GlobeNewswire)
Feb-05-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:05AM	Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 (GlobeNewswire)
Jan-31-26 08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-26-26 11:40AM	STVN or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-25-26 05:30AM	Can Trump and Big Pharma Get the World to Pay More for Drugs? (The Wall Street Journal)
Jan-22-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-26 04:05PM	Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-26 07:25PM	JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions (Pharmaceutical Technology)
Jan-12-26 11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
Jan-11-26 12:01PM	Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? (Benzinga)
Jan-09-26 08:00AM	Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor (GlobeNewswire) -7.58%
06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive)
Jan-08-26 11:40AM	UTHR or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-06-26 07:14PM	Why Madrigal Pharmaceuticals Stock Slumped on Tuesday (Motley Fool) -5.16%
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Jan-03-26 01:43PM	2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 (Motley Fool)
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-18-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.56%
Dec-15-25 04:05PM	Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-25 09:50AM	2 Predictions for Novo Nordisk in 2026 (Motley Fool)
Dec-11-25 07:44AM	H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data (Insider Monkey)
Dec-09-25 05:25PM	2 Stocks Up Over 600% in the Past 3 Years With More Room to Run (Motley Fool)
Dec-04-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:30AM	Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 07:58AM	Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug (Insider Monkey)
Nov-20-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 03:00AM	As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones (Pharma Voice)
Nov-18-25 07:31AM	Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? (Insider Monkey)
Nov-17-25 08:00AM	Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-14-25 05:05PM	John Paulson's Strategic Move: Significant Increase in Bausch Health Companies Inc. (GuruFocus.com)
Nov-10-25 08:00AM	Madrigal Presents New Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
Nov-06-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-25 10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks) +7.02%
06:26AM	Soleno slumps despite sales uptick; Madrigals MASH drug continues ascent (BioPharma Dive)
Nov-04-25 04:02PM	Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +7.83%
08:20AM	Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAUL FRIEDMAN	Director	Sep 28 '26	Proposed Sale	516.56	50,000	25,828,000		Sep 28 04:19 PM
Sibold William John	President and CEO	Sep 09 '26	Sale	535.59	6,362	3,407,397	202,967	Sep 11 04:57 PM
Sibold William John	President and CEO	Sep 11 '26	Sale	542.39	5,221	2,831,801	197,746	Sep 11 04:57 PM
WILLIAM SIBOLD	Director	Sep 11 '26	Proposed Sale	533.12	5,221	2,783,420		Sep 11 04:33 PM
William John Sibold	Officer and Director	Sep 09 '26	Proposed Sale	534.16	6,362	3,398,326		Sep 09 06:05 PM
Kelley Shannon T	General Counsel	Aug 17 '26	Sale	514.97	664	341,940	11,474	Aug 20 04:20 PM
Shannon Kelley	Officer	Aug 17 '26	Proposed Sale	507.56	664	337,020		Aug 20 04:18 PM
Sibold William John	President and CEO	Jul 20 '26	Sale	547.30	2,500	1,368,253	209,329	Jul 20 09:16 PM
William Sibold	Officer and Director	Jul 20 '26	Proposed Sale	553.48	2,500	1,383,700		Jul 20 09:11 PM
Soergel David	Chief Medical Officer	Jun 01 '26	Sale	495.74	1,042	516,561	10,033	Jun 01 07:49 PM
DAVID SOERGEL	Officer	Jun 01 '26	Proposed Sale	497.27	1,042	518,155		Jun 01 04:31 PM
Levy Richard S	Director	May 22 '26	Sale	515.44	5,682	2,928,716	22,015	May 22 06:01 PM
RICHARD LEVY	Director	May 22 '26	Proposed Sale	513.59	5,682	2,918,218		May 22 04:34 PM
Soergel David	Chief Medical Officer	May 18 '26	Sale	515.90	844	435,420	11,075	May 18 05:36 PM
David Soergel	Officer	May 18 '26	Proposed Sale	523.69	844	441,994		May 18 05:34 PM
Dier Mardi	EVP and CFO	Mar 06 '26	Sale	430.87	1,982	853,993	12,490	Mar 06 07:18 PM
Mardi Dier	Officer	Mar 06 '26	Proposed Sale	439.34	646	283,814		Mar 06 06:58 PM
Sibold William John	President and CEO	Mar 06 '26	Sale	431.94	1,663	718,316	161,829	Mar 06 06:49 PM
William Sibold	Officer and Director	Mar 06 '26	Proposed Sale	439.34	1,663	730,622		Mar 06 06:45 PM
Kelley Shannon T	General Counsel	Mar 06 '26	Sale	431.94	360	155,498	12,138	Mar 06 06:34 PM
Shannon Kelley	Officer	Mar 06 '26	Proposed Sale	439.34	360	158,162		Mar 06 06:28 PM
Huntsman Carole	Chief Commercial Officer	Mar 06 '26	Sale	431.94	419	180,983	12,692	Mar 06 06:15 PM
Carole Huntsman	Officer	Mar 06 '26	Proposed Sale	439.34	419	184,083		Mar 06 06:12 PM
Taub Rebecca	Director	Mar 06 '26	Sale	431.94	491	212,083	452,213	Mar 06 06:07 PM
Rebecca Taub	Director	Mar 06 '26	Proposed Sale	439.34	491	215,716		Mar 06 06:06 PM
MARDI DIER	Officer	Mar 06 '26	Proposed Sale	439.34	1,336	586,958		Mar 06 04:31 PM
Dier Mardi	EVP and CFO	Mar 02 '26	Sale	427.21	1,183	505,389	9,257	Mar 02 05:32 PM
Mardi Dier	Officer	Mar 02 '26	Proposed Sale	432.00	1,183	511,056		Mar 02 05:29 PM
Levy Richard S	Director	Feb 23 '26	Option Exercise	7.36	2,500	18,400	27,697	Feb 24 05:09 PM
Levy Richard S	Director	Jan 26 '26	Option Exercise	16.46	4,000	65,840	25,197	Jan 26 06:02 PM
Huntsman Carole	Chief Commercial Officer	Jan 26 '26	Sale	493.78	910	449,339	9,122	Jan 26 05:38 PM
Carole Huntsman	Officer	Jan 26 '26	Proposed Sale	480.45	340	163,353		Jan 26 05:35 PM
Sibold William John	President and CEO	Jan 26 '26	Sale	492.42	1,577	776,546	148,497	Jan 26 05:14 PM
William Sibold	Officer and Director	Jan 26 '26	Proposed Sale	480.45	1,577	757,670		Jan 26 05:11 PM
Taub Rebecca	Director	Jan 26 '26	Sale	492.42	647	318,596	452,704	Jan 26 05:05 PM
Rebecca Taub	Director	Jan 26 '26	Proposed Sale	480.45	647	310,851		Jan 26 05:02 PM
CAROLE A HUNTSMAN	Officer	Jan 26 '26	Proposed Sale	480.45	570	273,856		Jan 26 04:31 PM
Kelley Shannon T	General Counsel	Jan 20 '26	Sale	497.36	692	344,173	8,481	Jan 20 05:58 PM
Shannon Kelley	Officer	Jan 20 '26	Proposed Sale	501.68	263	131,942		Jan 20 05:54 PM
Taub Rebecca	Director	Jan 20 '26	Sale	490.77	2,238	1,098,343	453,351	Jan 20 05:46 PM
Rebecca Taub	Director	Jan 20 '26	Proposed Sale	501.68	2,238	1,122,760		Jan 20 05:38 PM
SHANNON KELLEY	Officer	Jan 20 '26	Proposed Sale	501.68	429	215,221		Jan 20 04:39 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Option Exercise	15.80	280	4,424	187,444	Jan 13 04:47 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Sale	551.24	280	154,348	187,164	Jan 13 04:47 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Option Exercise	15.80	24,520	387,416	211,684	Jan 13 04:43 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Sale	522.39	24,520	12,808,957	187,164	Jan 13 04:43 PM
Taub Rebecca	Director	Jan 09 '26	Option Exercise	15.80	240	3,792	455,829	Jan 13 04:38 PM
Taub Rebecca	Director	Jan 09 '26	Sale	550.33	240	132,080	455,589	Jan 13 04:38 PM
Taub Rebecca	Director	Jan 09 '26	Option Exercise	15.80	18,410	290,878	473,999	Jan 13 04:34 PM
Taub Rebecca	Director	Jan 09 '26	Sale	522.40	18,410	9,617,312	455,589	Jan 13 04:34 PM
REBECCA A TAUB	Director	Jan 09 '26	Proposed Sale	556.22	18,650	10,373,503		Jan 09 04:30 PM
FRIEDMAN PAUL A	Director	Dec 10 '25	Option Exercise	15.80	24,800	391,840	211,964	Dec 12 04:40 PM
FRIEDMAN PAUL A	Director	Dec 10 '25	Sale	552.18	24,800	13,694,158	187,164	Dec 12 04:40 PM
Taub Rebecca	Director	Dec 10 '25	Option Exercise	15.80	18,650	294,670	479,694	Dec 12 04:35 PM
Taub Rebecca	Director	Dec 10 '25	Sale	552.15	18,650	10,297,573	461,044	Dec 12 04:35 PM
PAUL FRIEDMAN	Director	Dec 10 '25	Proposed Sale	553.92	49,600	27,474,432		Dec 10 04:17 PM
REBECCA A TAUB	Director	Dec 10 '25	Proposed Sale	553.92	18,650	10,330,608		Dec 10 04:17 PM
Sibold William John	President and CEO	Dec 04 '25	Sale	575.34	2,400	1,380,816	150,074	Dec 04 05:26 PM
William John Sibold	Officer and Director	Dec 04 '25	Proposed Sale	579.89	2,400	1,391,736		Dec 04 05:06 PM
Dier Mardi	EVP and CFO	Dec 02 '25	Option Exercise	251.63	4,173	1,050,052	14,613	Dec 03 05:59 PM
Dier Mardi	EVP and CFO	Dec 02 '25	Sale	578.34	4,173	2,413,416	10,440	Dec 03 05:59 PM
MARDI C DIER	Officer	Dec 02 '25	Proposed Sale	579.45	4,173	2,418,045		Dec 02 04:23 PM
Huntsman Carole	Chief Commercial Officer	Nov 21 '25	Sale	553.11	1,958	1,082,986	10,032	Nov 21 05:39 PM
Carole Huntsman	Officer	Nov 21 '25	Proposed Sale	542.12	894	484,655		Nov 21 04:26 PM
Levy Richard S	Director	Nov 13 '25	Option Exercise	13.78	8,500	117,160	29,697	Nov 14 05:12 PM
Levy Richard S	Director	Nov 13 '25	Sale	520.96	8,500	4,428,198	21,197	Nov 14 05:12 PM
RICHARD S LEVY	Director	Nov 13 '25	Proposed Sale	528.94	8,500	4,495,990		Nov 13 04:26 PM
BATE KENNETH	Director	Nov 05 '25	Option Exercise	205.07	16,575	3,399,036	19,202	Nov 07 04:20 PM
BATE KENNETH	Director	Nov 05 '25	Sale	484.30	16,575	8,027,354	2,627	Nov 07 04:20 PM
KENNETH M BATE	Director	Nov 05 '25	Proposed Sale	484.30	16,575	8,027,354		Nov 05 04:15 PM

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

CEOMr. William J. Sibold

FounderDr. Rebecca A. Taub M.D.

Executive VP & CFOMs. Mardi C. Dier

Executive VPMs. Shannon Kelley

Executive VP & Chief Commercial OfficerMs. Carole Huntsman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Madrigal Pharmaceuticals Inc

Upgrade your Finviz experience